Cyrus J. Lawrence’s Medifast MED Stock Holding History

Cyrus J. Lawrence’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-129	Closed	-$15K	–	182
2022 Q4	$15K	Hold	129	–	–	﹤0.01%	193
2022 Q3	$13K	Hold	129	–	–	﹤0.01%	176
2022 Q2	$23K	Hold	129	–	–	0.01%	192
2022 Q1	$22K	Buy	+129	New	+$24.3K	0.01%	205

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Cyrus J. Lawrence's MED Position: Q1 2023 in Review

Cyrus J. Lawrence sold out of Medifast (MED) in Q1 2023, closing a stake of 129 shares — an estimated $15K sold.

Cyrus J. Lawrence first reported a position in MED in Q1 2022 and held it in 4 quarters. The position peaked at $23K in Q2 2022. 267 funds tracked by Wall St. Rank hold MED as of Q1 2023.

Cyrus J. Lawrence reported no remaining Medifast position as of Q1 2023 after selling out during the quarter.
Cyrus J. Lawrence sold 129 Medifast shares in Q1 2023, an estimated $15K.
Cyrus J. Lawrence first reported a position in Medifast in Q1 2022 and held it in 4 quarters.
Cyrus J. Lawrence's Medifast position peaked at $23K in Q2 2022.
267 funds tracked by Wall St. Rank held Medifast as of Q1 2023.

Based on Cyrus J. Lawrence's 13F filing for Q1 2023, filed 12 May 2023.